You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's reports, filings, earnings calls and investor events, most recent first. Search these from Claude or ChatGPT →
Satellos Bioscience Inc. changed BASECAMP’s primary efficacy endpoint following FDA feedback to change in vastus lateralis fat fraction measured by MRI, replacing dynamometry. Topline 12-week placebo-controlled data are expected in Q1 2027.
Satellos Bioscience Inc. formed a Scientific Advisory Board to guide research into regeneration, aging and neurodegenerative biology, with Janet Rossant serving as chair. The board will advise on stem cell biology, molecular signaling and disease pathology.
Satellos Bioscience Inc. management will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference on Nov. 9, 2026 and the Jefferies Global Healthcare Conference on Nov. 18-19, 2026, with investor meetings available during both events.
Satellos Bioscience Inc. received U.S. Patent No. 12,747,245 covering forazapadin’s composition of matter, providing protection through Sept. 6, 2044. Forazapadin advances in Phase 2 development, with an FSHD Phase 2 clinical study expected to begin in the fourth quarter of 2026.
Satellos Bioscience Inc. completed BASECAMP enrollment, meeting and surpassing its target in less than nine months; it now expects to report topline forazapadin data in the first quarter of 2027.
Satellos Bioscience Inc. announced FDA clearance for forazapadin’s IND application in FSHD; FSHD Canada Foundation will provide up to US$5 million over five quarters, supporting a Phase 2 study expected to begin in Q4 2026.
